Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017212 · ClinicalTrials.gov registry record · Phase 2
DX-8951f in Treating Patients With Metastatic Stomach Cancer
A Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Study locations
NCT00017212 is a Phase 2 study of Gastric Cancer and Esophageal Cancer that has completed, run by Daiichi Sankyo. The trial reports 6 study locations across 4 states.
The verdict
NCT00017212, a Phase 2 study of Gastric Cancer and Esophageal Cancer, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have metastatic stomach cancer.
Conditions Studied
Interventions
- DRUG exatecan mesylate
Study Locations (6)
Texas
- Simmons Cancer Center - Dallas - Dallas
- University of Texas - MD Anderson Cancer Center - Houston
- Cancer Therapy and Research Center - San Antonio
California
- Pacific Shores Medical Group - Long Beach
Colorado
- Rocky Mountain Cancer Centers - Denver
Ontario
- Cancer Care Ontario-Hamilton Regional Cancer Centre - Hamilton
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-04 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017212
The ClinicalTrials.gov registry entry for NCT00017212 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which exatecan mesylate is the first listed.
NCT00017212 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Texas, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00017212 about?
NCT00017212 is a clinical study titled "DX-8951f in Treating Patients With Metastatic Stomach Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have metastatic stomach cancer.
What is the current status of trial NCT00017212?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-04. Estimated completion is 2003-09.
What conditions does trial NCT00017212 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT00017212?
The interventions under investigation include: exatecan mesylate (DRUG).
Who is sponsoring clinical trial NCT00017212?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00017212 being conducted?
This trial has 6 study locations across California, Colorado, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.